Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ifedayo Victor Ogungbe has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Olamide Crown

    Chemistry and Biotechnology Science and Engineering Programs, The University of Alabama in Huntsville, 301 Sparkman Drive, Huntsville, Alabama 35899, United States

    7 shared publications
  • William Nathan Setzer

    Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA

    6 shared publications
  • Huaisheng Zhang

    Department of Chemistry, Jackson State University, Jackson, MS39217-0510, USA

    5 shared publications
  • Olawale S. Adeyinka

    Chemistry and Biotechnology Science and Engineering Programs, The University of Alabama in Huntsville, 301 Sparkman Drive, Huntsville, Alabama 35899, United States

    5 shared publications
  • Damilohun S. Metibemu

    Chemistry and Biotechnology Science and Engineering Program, College of Science, The University of Alabama in Huntsville, Huntsville, AL, 35899, USA

    4 shared publications
  • Aarthi Narayanan

    Department of Biology, College of Science, George Mason University, Fairfax, VA, 22030, USA

    3 shared publications

Latest Publications

  • Open Access

    Cathepsin Inhibitor Suppresses the Growth of Ectopic Hepatocellular Carcinoma Tumors in Mouse Models

    by Olamide Crown, Oluwatoyin V. Odubanjo, Olawale S. Adeyinka, Felicite K. Noubissi, Ifedayo Victor Ogungbe

    The advanced stages of hepatocellular carcinoma (HCC) are challenging to treat because of the invasion of blood vessels by malignant cells, as well as underlying cirrhosis in most patients. Current chemotherapeutic approaches are hindered by limited efficacy, systemic toxicity, and drug resistance. Therefore, developing new chemotherapeutic agents that can be used alone or as part of a cocktail regimen could aid in the treatment of HCC patients. This study primarily focuses on a cathepsin inhibitor and its antiproliferative effects on HCC cell lines in vitro and in HCC tumor xenografts in mouse models. The results show that the inhibitor has significant antiproliferative effects on the Hep G2 and Hep 3B cell lines, with low micromolar CC50 values. Furthermore, the compound inhibits both recombinant and endogenous cathepsin L and cathepsin S in a time-dependent manner. In mice, significant reductions in the growth of subcutaneous tumors relative to controls were observed, and it is well-tolerated when compared to Doxorubicin and Sorafenib. Transcriptomics analysis using RNA-Seq revealed that genes involved in regulating cell death, cell proliferation, and cellular processes were enriched in a time- and dose-dependent manner. Overall, the cathepsin inhibitor appears to be a promising starting point for further investigation as an antiproliferative agent.

  • Broad-spectrum inhibitor of non-structural protein 2 protease shows therapeutic efficacy against Venezuelan equine encephalitis viral infection

    by Olawale S. Adeyinka, Damilohun S. Metibemu, Tamia Hampton, Jane-Frances Chinenye Ojobor, Olamide Crown, John Falode, Michael D. Barrera, Farhang Alem, Aarthi Narayanan, Ifedayo Victor Ogungbe


  • Antibacterial Activities of Copper, Silver, and Zinc-Derived Nanoparticles and their Capacity to Enhance the Antimicrobial Activities of Antibiotics

    by Denise Yancey-Gray, Rogers Nyamwihura, Zikri Arslan, Ifedayo Victor Ogungbe

    Nanoparticles derived from copper (Cu), zinc (Zn), and silver (Ag) have bactericidal activities, are biocompatible, and are malleable to different structural designs/shapes, making them attractive as antibacterial agents. The development of new antibacterial agents is particularly important because the emergence of multidrug-resistant (MDR) bacteria driven by overuse, misuse, and abuse of antibiotics has become a global problem. Drug resistance results in higher mortality and morbidity, increase in treatment cost, and longer hospital stays. Unfortunately, over the past three decades, the lack of adequate investments in developing new drugs to replace current and ineffective ones has compounded the problem. This review provides a comprehensive insight into the investigation of nanoparticles derived from Cu, Zn, and Ag as antibacterial agents, especially when combined with antibiotics. It provides mechanistic details about the activities of the nanoparticles and their limited structure-activity relationships. In addition, the effect of doping and its impact on the antibacterial activity of the nanomaterials is discussed, as well as the nanoparticles’ ability to inhibit or reduce bacterial growth on surfaces and prevent the development of antibiotic resistance by biofilms.


  • nsP2 Protease Inhibitor Blocks the Replication of New World Alphaviruses and Offer Protection in Mice

    by Olawale S. Adeyinka, Michael D. Barrera, Damilohun S. Metibemu, Niloufar Boghdeh, Carol A. Anderson, Haseebullah Baha, Olamide Crown, John Adeolu Falode, Janard L. Bleach, Amanda R. Bliss, et al.

    New World alphaviruses, including Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV), are mosquito-transmitted viruses that cause disease in humans. These viruses are endemic to the western hemisphere, and disease in humans may lead to encephalitis and long-term neurological sequelae. There are currently no FDA-approved vaccines or antiviral therapeutics available for the prevention or treatment of diseases caused by these viruses. The alphavirus nonstructural protein 2 (nsP2) functions as a protease, which is critical for the establishment of a productive viral infection by enabling accurate processing of the nsP123 polyprotein. Owing to the essential role played by nsP2 in the alphavirus infectious process, it is also a valuable therapeutic target. In this article, we report the synthesis and evaluation of novel small molecule inhibitors that target the alphavirus nsP2 protease via a covalent mode of action. The two lead compounds demonstrated robust inhibition of viral replication in vitro. These inhibitors interfered with the processing of the nsP123 polyprotein as determined using VEEV TC-83 as a model pathogen and are active against EEEV and WEEV. The compounds were found to be nontoxic in two different mouse strains and demonstrated antiviral activity in a VEEV TC-83 lethal challenge mouse model. Cumulatively, the outcomes of this study provide a compelling rationale for the preclinical development of nsP2 protease inhibitors as direct-acting antiviral therapeutics against alphaviruses.


  • Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya

    by Damilohun S. Metibemu, Olawale S. Adeyinka, John Falode, Tamia Hampton, Olamide Crown, J. Chinenye Ojobor, Aarthi Narayanan, Justin Julander, Ifedayo Victor Ogungbe


  • Inhibitors of the Structural and Nonstructural Proteins of Alphaviruses

    by Damilohun Samuel Metibemu, Olawale Samuel Adeyinka, John Falode, Olamide Crown, Ifedayo Victor Ogungbe

    The Alphavirus genus includes viruses that cause encephalitis due to neuroinvasion and viruses that cause arthritis due to acute and chronic inflammation. There is no approved therapeutic for alphavirus infections, but significant efforts are ongoing, more so in recent years, to develop vaccines and therapeutics for alphavirus infections. This review article highlights some of the major advances made so far to identify small molecules that can selectively target the structural and the nonstructural proteins in alphaviruses with the expectation that persistent investigation of an increasingly expanding chemical space through a variety of structure-based design and high-throughput screening strategies will yield candidate drugs for clinical studies. While most of the works discussed are still in the early discovery to lead optimization stages, promising avenues remain for drug development against this family of viruses.


  • Discovery of an orally active nitrothiophene-based antitrypanosomal agent

    by Oluwatomi Ajayi, Damilohun S. Metibemu, Olamide Crown, Olawale S. Adeyinka, Marcel Kaiser, Nathalie Shoji, Mariana Silva, Ana Rodriguez, Ifedayo Victor Ogungbe


  • Open Access

    Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Therapeutics

    by Ericsson Coy-Barrera, Ifedayo Victor Ogungbe, Thomas J. Schmidt

    Natural products (NPs) from plants, fungi, animals, and microorganisms have historically played important roles in drug discovery


  • Open Access

    Inhibitors of the Ubiquitin-Mediated Signaling Pathway Exhibit Broad-Spectrum Antiviral Activities against New World Alphaviruses

    by Niloufar A. Boghdeh, Brittany McGraw, Michael D. Barrera, Carol Anderson, Haseebullah Baha, Kenneth H. Risner, Ifedayo V. Ogungbe, Farhang Alem, Aarthi Narayanan

    New World alphaviruses including Venezuelan Equine Encephalitis Virus (VEEV) and Eastern Equine Encephalitis Virus (EEEV) are mosquito-transmitted viruses that cause disease in humans and equines. There are currently no FDA-approved therapeutics or vaccines to treat or prevent exposure-associated encephalitic disease. The ubiquitin proteasome system (UPS)-associated signaling events are known to play an important role in the establishment of a productive infection for several acutely infectious viruses. The critical engagement of the UPS-associated signaling mechanisms by many viruses as host–pathogen interaction hubs led us to hypothesize that small molecule inhibitors that interfere with these signaling pathways will exert broad-spectrum inhibitory activity against alphaviruses. We queried eight inhibitors of the UPS signaling pathway for antiviral outcomes against VEEV. Three of the tested inhibitors, namely NSC697923 (NSC), bardoxolone methyl (BARM) and omaveloxolone (OMA) demonstrated broad-spectrum antiviral activity against VEEV and EEEV. Dose dependency and time of addition studies suggest that BARM and OMA exhibit intracellular and post-entry viral inhibition. Cumulatively, our studies indicate that inhibitors of the UPS-associated signaling pathways exert broad-spectrum antiviral outcomes in the context of VEEV and EEEV infection, supporting their translational application as therapeutic candidates to treat alphavirus infections.


  • Open Access

    Carotenoids in Drug Discovery and Medicine: Pathways and Molecular Targets Implicated in Human Diseases

    by Damilohun Samuel Metibemu, Ifedayo Victor Ogungbe

    Carotenoids are isoprenoid-derived natural products produced in plants, algae, fungi, and photosynthetic bacteria. Most animals cannot synthesize carotenoids because the biosynthetic machinery to create carotenoids de novo is absent in animals, except arthropods. Carotenoids are biosynthesized from two C20 geranylgeranyl pyrophosphate (GGPP) molecules made from isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) via the methylerythritol 4-phosphate (MEP) route. Carotenoids can be extracted by a variety of methods, including maceration, Soxhlet extraction, supercritical fluid extraction (SFE), microwave-assisted extraction (MAE), accelerated solvent extraction (ASE), ultrasound-assisted extraction (UAE), pulsed electric field (PEF)-assisted extraction, and enzyme-assisted extraction (EAE). Carotenoids have been reported to exert various biochemical actions, including the inhibition of the Akt/mTOR, Bcl-2, SAPK/JNK, JAK/STAT, MAPK, Nrf2/Keap1, and NF-κB signaling pathways and the ability to increase cholesterol efflux to HDL. Carotenoids are absorbed in the intestine. A handful of carotenoids and carotenoid-based compounds are in clinical trials, while some are currently used as medicines. The application of metabolic engineering techniques for carotenoid production, whole-genome sequencing, and the use of plants as cell factories to produce specialty carotenoids presents a promising future for carotenoid research. In this review, we discussed the biosynthesis and extraction of carotenoids, the roles of carotenoids in human health, the metabolism of carotenoids, and carotenoids as a source of drugs and supplements.